---
layout: default
title: Amoxicillin Trihydrate
parent: 僅模型預測 (L5)
nav_order: 36
evidence_level: L5
indication_count: 0
---

# Amoxicillin Trihydrate
{: .fs-9 }

證據等級: **L5** | 預測適應症: **0** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Amoxicillin Trihydrate: Repurposing Evaluation — Insufficient Data for Prediction

---

## One-Sentence Summary

Amoxicillin trihydrate is a broad-spectrum beta-lactam antibiotic widely used in clinical practice for the treatment of bacterial infections.
The current Evidence Pack contains **no TxGNN-predicted new indications** for this drug, and critical data including mechanism of action, safety information, and SAHPRA registration records are unavailable.
A complete drug repurposing evaluation **cannot be conducted** until the identified data gaps are resolved.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | Not available in this Evidence Pack |
| Predicted New Indication | None — no TxGNN predictions generated |
| TxGNN Prediction Score | N/A |
| Evidence Level | L5 — No predictions or supporting studies available |
| South Africa Market Status | Not Registered |
| Number of SAHPRA Registrations | 0 |
| Recommended Decision | Hold |

---

## Why is This Prediction Reasonable?

No predicted indications are present in this Evidence Pack, so a mechanistic rationale for drug repurposing cannot be provided at this time.

Mechanism of action (MOA) data was also not retrieved. From established pharmacological knowledge, amoxicillin trihydrate is a beta-lactam antibiotic that inhibits bacterial cell wall synthesis by irreversibly binding to penicillin-binding proteins (PBPs), blocking the final transpeptidation step in peptidoglycan cross-linking and ultimately leading to cell lysis. However, this information was not confirmed via DrugBank in the current data pull (DrugBank ID is unassigned in this pack) and should be formally verified before proceeding to any repurposing analysis.

To generate a repurposing prediction, amoxicillin trihydrate must first be processed through the TxGNN knowledge graph (KG) and deep learning (DL) prediction pipeline. Once predictions are available, mechanistic plausibility between the original antibiotic indication and any candidate new indication can be assessed.

---

## Clinical Trial Evidence

Currently no related clinical trials registered — no predicted repurposing indications have been generated for this drug.

---

## Literature Evidence

Currently no related literature available — no predicted repurposing indications have been generated for this drug.

---

## South Africa Market Information

No SAHPRA registrations were found for Amoxicillin Trihydrate in this Evidence Pack.

> **Important note for practitioners:** Amoxicillin is one of the most widely prescribed antibiotics globally and appears on the WHO Essential Medicines List. The absence of SAHPRA registration data for this specific salt form (trihydrate) in the current Evidence Pack is likely a data retrieval issue rather than a true absence from the South African market. This must be verified directly against the [SAHPRA Online Medicines Register](https://www.sahpra.org.za/list-of-approved-medicines/) before drawing any regulatory conclusions. Other formulations or presentations of amoxicillin may be registered under different licence entries.

---

## Safety Considerations

Please refer to the SAHPRA-approved Professional Information (PI) for safety information. Report adverse drug reactions to SAHPRA.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The Evidence Pack for Amoxicillin Trihydrate is critically incomplete — no TxGNN repurposing predictions have been generated, zero SAHPRA licences are recorded, and both the safety profile and mechanism of action data are absent. There is no basis on which to conduct or conclude a repurposing evaluation at this stage.

**To proceed, the following is needed:**

- **[Blocking — DG001]** Download and parse the SAHPRA-approved Professional Information (PI) to extract warnings, contraindications, and drug interactions
- **[High — DG002]** Retrieve MOA and pharmacological data from the DrugBank API; a DrugBank ID must first be assigned to this drug record
- **[Pipeline]** Run the TxGNN KG and DL prediction pipeline to generate repurposing candidate indications and associated prediction scores
- **[Regulatory]** Manually verify SAHPRA registration status for amoxicillin trihydrate and all related formulations via the SAHPRA online register
- **[Data Quality]** Investigate why `total_licenses = 0` and `market_status = "未上市"` — confirm whether this reflects a true gap in SAHPRA registration data or a query/mapping error in the data pipeline

> *This report is for research reference only and does not constitute medical advice. All drug repurposing candidates require clinical validation before any therapeutic application.*
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

